| Ipilimumab (n = 70) | ||||
---|---|---|---|---|---|
PET parameter | Level | n | HR | HR 95% CI | P-value |
Tumoral SUVmax | Â | Â | 0.983 | [0.95,1.01] | 0.24 |
MTV | Â | Â | 1.000 | [1.00, 1.001] | 0.03 |
SLR | Â | Â | 18.71 | [1.34, 261.25] | 0.02 |
Tumoral SUVmax | < 16.07 | 35 | 1 | – |  |
> 16.07 | 35 | 0.83 | [0.42, 1.63] | 0.59 | |
MTV (mL) | < 41.38 | 35 | 1 | – |  |
> 41.38 | 35 | 1.09 | [0.52, 2.29] | 0.83 | |
SLR | < 1.1 | 59 | 1 | – |  |
> 1.1 | 10 | 5.83 | [2.31–14.74] | 0.0002 | |
 | Anti-PD1 (n = 40) | ||||
PET parameter | Level | n | HR | HR 95% CI | P-value |
Tumoral SUVmax | Â | Â | 0.967 | [0.93, 1.007] | 0.10 |
MTV | Â | Â | 1.000 | [0.9995, 1.001] | 0.49 |
SLR | Â | Â | 2.419 | [0.08, 76.00] | 0.62 |
Tumoral SUVmax | < 19.33 | 20 | 1 | – |  |
> 19.33 | 20 | 0.57 | [0.21, 1.53] | 0.27 | |
MTV (mL) | < 137 | 20 | 1 | – |  |
> 137 | 20 | 1.67 | [0.64, 4.34] | 0.29 | |
SLR | < 1.1 | 35 | 1 | – |  |
> 1.1 | 5 | 0.92 | [0.26, 3.29] | 0.89 | |
 | First line immunotherapy (n = 90) | ||||
PET parameter | Level | n | HR | HR 95% CI | P-value |
Tumoral SUVmax | Â | Â | 0.986 | [0.964, 1.01] | 0.21 |
MTV | Â | Â | 1.09 | [1.02, 1.15] | 0.02 |
SLR | Â | Â | 17.3 | [1.90, 157] | 0.02 |
Tumoral SUVmax | ≤18 | 49 | 1 | – | 0.05 |
> 18 | 41 | 0.57 | [0.32, 1.01] |  | |
MTV (mL) | ≤76 | 51 | 1 | – | 0.61 |
> 76 | 39 | 1.18 | [0.63, 2.23] |  | |
SLR | ≤1.1 | 79 | 1 | – | 0.003 |
> 1.1 | 10 | 3.92 | [1.76, 8.72] |  |